Recombinant Human IDO-1 Protein

IDO-1 (Indoleamine 2,3-dioxygenase 1) is an enzyme involved in the catabolism of tryptophan, an essential amino acid, into kynurenine. It plays a critical role in immune regulation and has garnered significant attention in cancer research, as it is often upregulated in tumors, contributing to immune evasion by suppressing T cell activity and promoting regulatory T cell (Treg) generation. The overexpression of IDO-1 in various tumor types, including melanoma, lung cancer, and breast cancer, has been linked to poor prognosis, indicating its potential as a therapeutic target. The enzyme's activity not only affects tumor microenvironments but also has implications in other pathologies, such as autoimmune diseases, infections, and neurodegenerative disorders. Researchers are investigating IDO-1 inhibitors as part of cancer immunotherapy strategies aimed at reinvigorating T cell responses and improving the effectiveness of existing treatments, such as checkpoint inhibitors. Understanding the molecular mechanisms by which IDO-1 operates, as well as its interactions with other immune modulators, is crucial to developing novel therapeutic approaches. Additionally, IDO-1's role in altering systemic metabolism and influencing the microbiome further emphasizes the complexity of its function in health and disease. Given these factors, IDO-1 represents a promising candidate for targeted therapies, warranting ongoing research to elucidate its full potential in clinical applications.